Abdalla SA, Letarte M: Hereditary haemorrhagic
telangiectasia: current views on genetics and
mechanisms of disease. J Med Genet 43:97–110,
2006.
Albiñana V, Bernabeu-Herrero ME, Zarrabeitia R,
Bernabéu C, Botella LM: Estrogen therapy for
hereditary haemorrhagic telangiectasia (HHT):
Effects of raloxifene, on Endoglin and ALK1
expression in endothelial cells. Thromb Haemost
103:525–534, 2010.
Bellon T, Corbi A, Lastres P, Cales C, Cebrián M,
Vera S, Cheifetz S, Massague J, Letarte M,
Bernabéu C: Identification and expression of two
forms of the human transforming growth
factor-beta-binding protein endoglin with distinct
cytoplasmic regions. Eur J Immunol
23:2340–2345, 1993.
Bernabéu C, Conley BA, Vary CP: Novel
biochemical pathways of endoglin in vascular cell
physiology. J Cell Biochem 102:1375–1388,
2007.
Bernabéu C, López-Novoa JM, Quintanilla M: An
emerging role of TGF-β co-receptors in cancer.
Biochem Biophys Acta 1792:954–973, 2009.
Blanco FJ, Santibanez JF, Guerrero-Esteo M, Langa
C, Vary CP, Bernabéu C: Interaction and
functional interplay between endoglin and ALK-1,
two components of the endothelial transforming
growth factor-beta receptor complex. J Cell
Physiol 204:574–584, 2005.
Blanco FJ, Grande MT, Langa C, Oujo B, Velasco S,
Rodríguez-Barbero A, Pérez-Gómez E,
Quintanilla M, López-Novoa JM, Bernabéu C:
S-endoglin expression is induced in senescent
endothelial cells and contributes to vascular
pathology. Circ Res 103:1383–1392, 2008.
Botella LM, Sánchez-Elsner T, Rius C, Corbí A,
Bernabéu C: Identification of a critical Sp1 site
within the endoglin promoter and its involvement
in the transforming growth factor-beta
stimulation. J Biol Chem 276:34486–3494, 2001.
Botella LM, Sánchez-Elsner T, Sanz-Rodriguez F,
Kojima S, Shimada J, Guerrero-Esteo M,
Cooreman MP, Ratziu V, Langa C, Vary CP,
Ramirez JR, Friedman S et al.: Transcriptional
activation of endoglin and transforming growth
factor-beta signaling components by cooperative
interaction between Sp1 and KLF6: their potential
role in the response to vascular injury. Blood
100:4001–4010, 2002.
David L, Feige JJ, Bailly S: Emerging role of bone
morphogenetic proteins in angiogenesis. Cytokine
Growth Factor Rev 20:203–212, 2009.
Faughnan ME, Palda VA, Garcia-Tsao G, Geisthoff
UW, McDonald J, Proctor DD, Spears J, Brown
DH, Buscarini E, Chesnutt MS, Cottin V,
Ganguly A et al.: International Guidelines for the
Diagnosis and Management of Hereditary
Hemorrhagic Telangiectasia. J Med Genet
published online June 23, 2009
doi:10.1136/jmg.2009.069013
Fernández-L A, Sanz-Rodriguez F, Zarrabeitia R,
Pérez-Molino A, Hebbel RP, Nguyen J, Bernabéu
C, Botella LM: Blood outgrowth endothelial cells
from hereditary haemorrhagic telangiectasia
patients reveal abnormalities compatible with
vascular lesions. Cardiovasc Res 68:235–248,
2005.
Fernández-L A, Garrido-Martin EM, Sanz-Rodriguez
F, Ramirez JR, Morales-Angulo C, Zarrabeitia R,
Pérez-Molino A, Bernabéu C, Botella LM:
Therapeutic action of tranexamic acid in
hereditary haemorrhagic telangiectasia (HHT):
regulation of ALK-1/endoglin pathway in
endothelial cells. Thromb Haemost 97:254–262,
2007.
Fernández-Ruiz E, St-Jacques S, Bellón T, Letarte M,
Bernabéu C: Assignment of the human endoglin
gene (END) to 9q34>qter. Cytogenet Cell Genet
64:204–207, 1993.
Fonsatti E, Nicolay HJ, Altomonte M, Covre A, Maio
M: Targeting cancer vasculature via
endoglin/cd105: a novel antibody-based
diagnostic and therapeutic strategy in solid
tumors. Cardiovasc Res 86:12–19, 2010.
Fontalba A, Fernández-L A, García-Alegria E,
Albiñana V, Garrido-Martin EM, Blanco FJ,
Zarrabeitia R, Pérez-Molino A, Bernabeu-Herrero
ME, Ojeda ML, Fernandez-Luna JL, Bernabéu C
et al.: Mutation study of Spanish patients with
hereditary hemorrhagic telangiectasia. BMC Med
Genet 9:75, 2008.
Gallione C, Aylsworth AS, Beis J, Berk T, Bernhardt
B, Clark RD, Clericuzio C, Danesino C, Drautz J,
Fahl J, Fan Z, Faughnan ME et al.: Overlapping
spectra of SMAD4 mutations in juvenile
polyposis (JP) and JP-HHT syndrome. Am J Med
Genet A 152A:333–339, 2010.
Gordon KJ, Blobe GC: Role of transforming growth
factor-beta superfamily signaling pathways in
human disease. Biochim Biophys Acta
1782:197–228, 2008.
Gougos A, Letarte M: Primary structure of endoglin,
an RGD-containing glycoprotein of human
endothelial cells. J Biol Chem 265:8361–8364,
1990.
Goumans MJ, Liu Z, ten Dijke P: TGF-beta signaling
in vascular biology and dysfunction. Cell Res
19:116–127, 2009.
Govani FS, Shovlin CL: Hereditary haemorrhagic
telangiectasia: a clinical and scientific review. Eur
J Hum Genet 17:860–871, 2009.
Guerrero-Esteo M, Sánchez-Elsner T, Letamendia A,
Bernabéu C: Extracellular and cytoplasmic
domains of endoglin interact with the
transforming growth factor-beta receptors I and II.
J Biol Chem 277:29197–29209, 2002.
Henry-Berger J, Mouzat K, Baron S, Bernabéu C,
Marceau G, Saru JP, Sapin V, Lobaccaro JM,
Caira F: Endoglin (CD105) expression is
regulated by the liver X receptor alpha (NR1H3)
in human trophoblast cell line JAR. Biol Reprod
78:968–975, 2008.
Jerkic M, Rivas-Elena JV, Santibanez JF, Prieto M,
Rodríguez-Barbero A, Perez-Barriocanal F,
Pericacho M, Arévalo M, Vary CP, Letarte M,
Bernabéu C, López-Novoa JM: Endoglin
regulates cyclooxygenase-2 expression and
activity. Circ Res 99:248–256, 2006.
Johnson DW, Berg JN, Baldwin MA, Gallione CJ,
Marondel I, Yoon SJ, Stenzel TT, Speer M,
Pericak-Vance MA, Diamond A, Guttmacher AE,
Jackson CE et al.: Mutations in the activin
receptor-like kinase 1 gene in hereditary
haemorrhagic telangiectasia type 2. Nat Genet
13:189–195, 1996.
Jovine L, Darie CC, Litscher ES, Wassarman PM:
Zona pellucida domain proteins. Annu Rev
Biochem 74:83–114, 2005.
Lebrin F, Mummery CL: Endoglin-mediated vascular
remodeling: mechanisms underlying hereditary
haemorrhagic telangiectasia. Trends Cardiovasc
Med 18:25–32, 2008.
Li X, Yonenaga Y, Seki T: Shortened ALK1
regulatory fragment maintains a specific activity
in arteries feeding ischemic tissues. Gene Ther
16:1034–1041, 2009.
Llorca O, Trujillo A, Blanco FJ, Bernabéu C:
Structural model of human endoglin, a
transmembrane receptor responsible for hereditary
hemorrhagic telangiectasia. J Mol Biol
365:694–705, 2007.
Mannucci PM: Hemostatic drugs. N Engl J Med
339:245–253, 1998.
McAllister KA, Grogg KM, Johnson DW, Gallione
CJ, Baldwin MA, Jackson CE, Helmbold EA,
Markel DS, McKinnon WC, Murrell J,
McCormick MK, Pericak-Vance MA et al.:
Endoglin, a TGF-β binding protein of endothelial
cells, is the gene for hereditary haemorrhagic
telangiectasia type 1. Nat Genet 8:345–351, 1994.
Pérez-Gómez E, Eleno N, López-Novoa JM, Ramirez
JR, Velasco B, Letarte M, Bernabéu C,
Quintanilla M: Characterization of murineS-endoglin isoform and its effects on tumor
development. Oncogene 24:4450–4461, 2005.
Pérez-Gómez E, Villa-Morales M, Santos J,
Fernández-Piqueras J, Gamallo C, Dotor J,
Bernabéu C, Quintanilla M: A role for endoglin as
a suppressor of malignancy during mouse skin
carcinogenesis. Cancer Res 67:10268–10277,
2007.
Pimanda JE, Chan WY, Wilson NK, Smith AM,
Kinston S, Knezevic K, Janes ME, Landry JR,
Kolb-Kokocinski A, Frampton J, Tannahill D,
Ottersbach K et al.: Endoglin expression in blood
and endothelium is differentially regulated by
modular assembly of the Ets/Gata hemangioblast
code. Blood 112:4512–4522, 2008.
Plauchu H, de Chadarévian JP, Bideau A, Robert JM:
Age-related clinical profile of hereditary
hemorrhagic telangiectasia in an
epidemiologically recruited population. Am J Med
Genet 32:291–297, 1989.
Rius C, Smith JD, Almendro N, Langa C, Botella
LM, Marchuk DA, Vary CP, Bernabéu C:
Cloning of the promoter region of human
endoglin, the target gene for hereditary
hemorrhagic telangiectasia type 1. Blood
92:4677–4690, 1998.
Sabba C, Gallitelli M, Palasciano G: Efficacy of
unusually high doses of tranexamic acid for the
treatment of epistaxis in hereditary hemorrhagic
telangiectasia. N Engl J Med 345:926, 2001.
Sánchez-Elsner T, Botella LM, Velasco B, Langa C,
Bernabéu C: Endoglin expression is regulated by
transcriptional cooperation between the hypoxia
and transforming growth factor-β pathways. J Biol
Chem 277:43799–43808, 2002.
Santibanez JF, Letamendia A, Perez-Barriocanal F,
Silvestri C, Saura M, Vary CP, López-Novoa JM,
Attisano L, Bernabéu C: Endoglin increases
eNOS expression by modulating Smad2 protein
levels and Smad2-dependent TGF-beta signaling.
J Cell Physiol 210:456–468, 2007.
Santibanez JF, Blanco FJ, Garrido-Martin EM,
Sanz-Rodriguez F, del Pozo MA, Bernabéu C:
Caveolin-1 interacts and cooperates with the
transforming growth factor-beta type I receptor
ALK1 in endothelial caveolae. Cardiovasc Res
77:791–799, 2008.
Sanz-Rodriguez F, Guerrero-Esteo M, Botella LM,
Banville D, Vary CP, Bernabéu C: Endoglin
regulates cytoskeletal organization through
binding to ZRP-1, a member of the Lim family of
proteins. J Biol Chem 279:32858–32868, 2004.
Shovlin CL, Guttmacher AE, Buscarini E, Faughnan
ME, Hyland RH, Westermann CJ, Kjeldsen AD,
Plauchu H: Diagnostic criteria for hereditary
hemorrhagic telangiectasia (Rendu-Osler-Weber
syndrome). Am J Med Genet 91:66–67, 2000.
Velasco S, Alvarez-Muñoz P, Pericacho M, Dijke PT,
Bernabéu C, López-Novoa JM,
Rodríguez-Barbero A: L- and S-endoglin
differentially modulate TGFbeta1 signaling
mediated by ALK1 and ALK5 in L6E9 myoblasts.
J Cell Sci 121:913–919, 2008.
Wong VC, Chan PL, Bernabéu C, Law S, Wang LD,
Li JL, Tsao SW, Srivastava G, Lung ML:
Identification of an invasion and
tumor-suppressing gene, Endoglin (ENG),
silenced by both epigenetic inactivation and
allelic loss in esophageal squamous cell
carcinoma. Int J Cancer 123:2816–2823, 2008.
Zacharski LR, Dunbar SD, Newsom WA, Jr.:
Hemostatic effects of tamoxifen in HHT. Thromb
Haemost 85:371–372, 2001.
Altmetric
Altmetric